Zhihong O’Brien

发表

A Systematic Analysis of Physicochemical and ADME Properties of All Small Molecule Kinase Inhibitors Approved by US FDA from January 2001 to October 2015

M. Moghaddam, Z. O’Brien, Zhihong O’Brien, 2017, Current medicinal chemistry.

Pharmacokinetics and Pharmacodynamics of LGD-3303 [9-Chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quinolin-7(6H)-one], an Orally Available Nonsteroidal-Selective Androgen Receptor Modulator

P. Rix, E. Vajda, William Y. Chang, 2009, Journal of Pharmacology and Experimental Therapeutics.

Small molecule kinase inhibitors approved by the FDA from 2000 to 2011: a systematic review of preclinical ADME data

Z. O’Brien, Mehran Fallah Moghaddam, Zhihong O’Brien, 2013, Expert opinion on drug metabolism & toxicology.

A proposed screening paradigm for discovery of covalent inhibitor drugs.

A. Kulkarni, M. Moghaddam, Z. O’Brien, 2014, Drug metabolism letters.

Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.

J. Díaz, S. Lechner, D. Slee, 2008, Journal of medicinal chemistry.

Pharmacokinetics, in vitro absorption and metabolism of perillyl alcohol, a chemopreventive and chemotherapeutic agent

Z. O’Brien, Zhihong O’Brien, 2004 .

A pharmacokinetic evaluation of five H(1) antagonists after an oral and intravenous microdose to human subjects.

R. C. Garner, G. Beaton, P. Crowe, 2009, British journal of clinical pharmacology.

Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia.

M. Bradbury, F. Jovic, G. Beaton, 2009, Journal of medicinal chemistry.

Abstract 5917: A novel lipid nanoparticle (NBF-006) encapsulating glutathione S-transferase P (GSTP) siRNA for the treatment of KRAS-driven non-small cell lung cancer

J. Harborth, S. Zabludoff, J. Clamme, 2018 .

Novel benzothiophene H1-antihistamines for the treatment of insomnia.

Siobhan Malany, Bin-Feng Li, M. Bradbury, 2010, Bioorganic & medicinal chemistry letters.

2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 2. Reduction of hERG activity, observed species selectivity, and structure-activity relationships.

J. Díaz, S. Lechner, D. Slee, 2008, Journal of medicinal chemistry.